Novel tryptophan dioxygenase inhibitors and combined tryptophan dioxygenase/5-HT reuptake inhibitors

Bioorganic and Medicinal Chemistry Letters

Volumn 6, Issue 7, 1996, Pages 857-860

  Madge, D J ^a   Hazelwood, R ^b   Iyer, R ^b   Jones, H T ^b   Salter, M ^b  

^a Cruciform Project   (United Kingdom)

^b WELLCOME RESEARCH LABORATORIES   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

6 FLUORO 3 [2 (4 PYRIDYL)VINYL]INDOLE; ANTIDEPRESSANT AGENT; ENZYME INHIBITOR; FLUOXETINE; FLUVOXAMINE; INDOLE DERIVATIVE; SEROTONIN; SEROTONIN UPTAKE INHIBITOR; TRYPTOPHAN; TRYPTOPHAN 2,3 DIOXYGENASE; TRYPTOPHAN 2,3 DIOXYGENASE INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CEREBROSPINAL FLUID; CONTROLLED STUDY; DRUG DESIGN; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME INHIBITION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; INTRAPERITONEAL DRUG ADMINISTRATION; NONHUMAN; NUCLEAR MAGNETIC RESONANCE; ORAL DRUG ADMINISTRATION; QUANTITATIVE STRUCTURE ACTIVITY RELATION; RAT; STEREOCHEMISTRY; TRYPTOPHAN EMBOLISM;

ANIMALIA;

EID: 0029914364     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/0960-894X(96)00124-2     Document Type: Article

References (25)

1. Stahl, S.M.; Palazidou, L. Trends in Pharmacol. Sci. 1986, 9, 349.
2. Hollister, L.E.; Claghorn, J.L. Annu. Rev. Pharmacol. Toxicol, 1993, 32, 165.
3. Asberg, M.; Traskman, L.; Thoren, P. Arch. Gen. Psychiat., 1976, 33, 93.
4. Cooper, S.J.; Kelley, C.B.; King, D.J. Lancet, 1992, 340, 940.
5. Blier, P.; de Montigny, C.; Chaput, Y. Clin. Neuropharm., 1988, 11, S1.
6. Young, S.N.; Pihl, R.O.; Ervin, F.R. Clin. Neuropharm., 1988, 11, S207.
7. Heninger, G.R.; Delgado,P.L.; Charney, D.S.; Price, L.H.; Aghajanian, G.K. J. Chem. Neuroanat., 1992, 5, 347.
8. Bel, N.; Artigas, F. Synapse, 1993, 15, 243.
9. Walinder, J.; Skott, A.; Carlsson, A.; Nagy, A.; Roos, B-E. Arch. Gen. Psychiat., 1976, 33, 1384.
10. Young, S.N. J. Psychiatr. Neurosci., 1991,16, 241.
11. Pogson, C.I.; Knowles, R.G., Salter, M. Crit. Rev. Neurobiol., 1989, 5, 29.
12. Moller, S.E.; Kirk, L.; Honore, P. Psychopharmacol, 1982, 76, 79
13. Salter, M.; Knowles, R.G.; Pogson, C.I. Biochem. J., 1986, 234, 635.
14. Young, S.N. Nutrition and the Brain, pp 49-87, Wurtman, R.J.; Wurtman, J. J. Eds.; Raven Press, New York, 1986.
15. Salter, M.; Hazelwood, R.; Pogson, C.I.; Iyer, R.; Madge, D.J. Biochem. Pharmacol, 1995, 49, 1435.
16. All measurements of TDO inhibition are an average of at least 4 recordings and are ± 5nM. Briefly, rat liver was homogenised in potassium phosphate buffer (pH 7.0) containing tryptophan (1mM) and methaemoglobin, then centrifuged and the supernatant incubated with the inhibitor at 37°C for 1hr. Perchloric acid was added to stop the reaction and the mixture centrifuged then the supernatant analysed by HPLC (ZORBAX ODS column) for L-kynurenine. See ref. 15 for full details.
17. 1H NMR, MS and microanalysis properties.
18. Jones, G. Org. React., 1967, 15, 204.
19. Cavallito, C.J.; Yun, H.S. J. Med. Chem., 1969,12, 134.
20. 1H NMR typically showed a 16-18Hz coupling between the vinylic protons.
21. Clark, R.D.; Repke, D.B. Heterocycles, 1984, 22, 195.
22. Smith, G.F. J. Chem. Soc., 1954, 3842.
23. Salter, M.; Hazelwood, R.; Pogson, P.I., Iyer, R.; Madge, D.J.; Jones, H.T.; Cooper, B.R., Cox, R.F.; Wang, C.M.; Wiard, R.P. Neuropharmacology, 1995, 34, 217.
24. All quoted tryptophan and 5-HT elevation figures are a mean of 6 recordings.
25. 3H]-HT and measuring uptake on a scintillation counter after incubation with inhibitor. See ref. 23 for full details.